Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Keystone Symposium on Growing to Extremes: Cell Biology and Pathology of Axons
Glossopharyngeal neuralgia secondary to vascular compression in a patient with multiple sclerosis: a case report.
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
[Multiple sclerosis : actuality and therapeutic prospects].
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway.
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Pharmaceutical approval update.
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.

Pages